Taiko Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the year ending December 31, 2022. For the year ending December 31, 2022, the company expects net sales of JPY 6,000 million, operating loss of JPY 2,800 million and net loss of JPY 3,300 million or JPY 75.67 per basic share.